[1]陈 慎,杜明君,宋雅琴.宫颈组织HPV DNA与血清Chemerin,Leptin水平联合检测对宫颈癌早期诊断的价值分析[J].现代检验医学杂志,2019,34(03):42-46.[doi:10.3969/j.issn.1671-7414.2019.03.010]
　CHEN Shen,DU Ming-jun,SONG Ya-qin.Value of Combined Detection of HPV DNA and Serum Levelsof Chemerin and Leptin in Early Diagnosis of Cervical Cancer[J].Journal of Modern Laboratory Medicine,2019,34(03):42-46.[doi:10.3969/j.issn.1671-7414.2019.03.010]
点击复制

宫颈组织HPV DNA与血清Chemerin,Leptin水平联合检测对宫颈癌早期诊断的价值分析()
分享到：

《现代检验医学杂志》[ISSN:/CN:]

卷:
第34卷
期数:
2019年03期
页码:
42-46
栏目:
论著
出版日期:
2019-06-20

文章信息/Info

Title:
Value of Combined Detection of HPV DNA and Serum Levelsof Chemerin and Leptin in Early Diagnosis of Cervical Cancer
文章编号:
1671-7414(2019)03-042-05
作者:
陈 慎; 杜明君; 宋雅琴
(珠海市中西医结合医院检验科 珠海市第二人民医院,广东珠海 519000)
Author(s):
CHEN Shen; DU Ming-jun; SONG Ya-qin
(Department of Clinical Laboratory,Zhuhai Hospital of IntegratedTraditional Chineseand Western Medicine,Zhuhai Second People's Hospital,Guangdong Zhuhai519000,China)
关键词:
宫颈癌;  人乳头状瘤病毒DNA;  趋化素;  瘦素;  特异度;  敏感度
分类号:
R737.33; R730.43
DOI:
10.3969/j.issn.1671-7414.2019.03.010
文献标志码:
A
摘要:
目的 探讨人乳头状瘤病毒(human papillomavirus,HPV)DNA联合趋化素(chemerin)、瘦素(leptin)检测用于宫颈癌早期诊断的特异度与敏感度。方法 以2015年3月～2018年3月期间于珠海市第二人民医院诊治的82例宫颈癌患者、78例宫颈上皮瘤变(cervical intraepithelial neoplasias,CIN)患者分别为宫颈癌组和CIN组,76例同期于珠海市第二人民医院体检正常者为对照组。分析HPV DNA,Chemerin和Leptin单独及联合检测的敏感度及特异度。结果 宫颈癌组、CIN组和对照组的血清Chemerin水平依次降低,差异均具有统计学意义(P<0.05); 三组的HPV DNA阳性率差异具有统计学意义(P<0.05),经两两比较显示,宫颈癌组高于CIN组和对照组(P<α'); 宫颈癌组的中位Leptin浓度高于CIN组和对照组,差异具有统计学意义(P<0.05)。HPV DNA+Chemerin+Leptin平行联合检测的敏感度、特异度、准确度分别为47.56%,75.64%和61.25%,其中特异度和准确度均高于其中任意两者平行联合检测。HPV DNA+Chemerin+Leptin系列联合检测的敏感度、特异度、准确度分别为74.39%,74.36%和74.38%,均高于任意两者系列联合检测。HPV DNA+ Chemerin,Chemerin+ Leptin,HPV DNA+ Leptin和HPV DNA+ Chemerin+ Leptin平行联合检测的受试者工作特征(receiver operating characteristic curve,ROC)曲线下面积依次为0.735,0.717,0.654和0.818,(P<0.05),系列联合检测的ROC曲线下面积依次为0.709,0.697,0.650和0.860,(P<0.05)。结论 HPV DNA+Chemerin+Leptin系列联合检测可提高宫颈癌诊断的灵敏度、特异度、准确度和ROC曲线下面积,与平行联合检测相比,特异度仅略有下降,因此系列联合检测可有效提高诊断效能,利于宫颈癌的早期发现,及早干预。
Abstract:
Objective To study the specificity and sensitivity analysis of HPV DNA combined with Chemerin and Leptin detection in early diagnosis of cervical cancer.Methods From March 2015 to March 2018,82 patients with cervical cancer and 78 patients with cervical intraepithelial neoplasia were treated in Zhuhai Hospital of Inegrated Traditional Chinese and Western Medicine,and 76 cases of normal physical examination in ZhuhaiHospital of Inegrated Traditional Chinese and Western Medicine in the same periodwere selected as the control group.The sensitivity and specificity of HPV DNA,Chemerin and Leptin separately and combined detection were analyzed.Results The level of serum Chemerin in cervical cancer group,CIN group and control group decreased in turn,and the difference was statistically significant(P<0.05).The positive rate of HPV DNA in the three groups was statistically different(P<0.05).The two-two comparison showed that the cervical cancer group was higher than the CIN group and the control group(P<α').The median concentration of Leptin in cervical cancer group was higher than that in CIN group and control group(P<0.05).The sensitivity,specificity and accuracy of HPV DNA+ Chemerin+Leptin parallel combined detection were 47.56%,75.64% and 61.25% respectively,and the specificity and accuracy were higher than the parallel combined detection of any two of them.The sensitivity,specificity and accuracy of HPV DNA+ Chemerin+Leptin series combined detection were 74.39%,74.36% and 74.38% respectively,and they were higher than the series combined detection of any two of them.The areas under the ROC curve of HPVDNA+ Chemerin,Chemerin+ Leptin,HPV DNA+ Leptin and HPV DNA+ Chemerin+ Leptin parallel combined test were 0.735,0.717,0.654 and 0.818,respectively(P<0.05),and that under the ROC curve of the serial combined test were 0.709,0.697,0.650 and 0.860,respectively(P<0.05).ConclusionHPV DNA+ Chemerin+ Leptin series combined detection can improve the sensitivity,specificity,accuracy and area under the ROC curve of cervical cancer diagnosis.Compared with parallel combined detection,the specificity was onlyslightly decreased.Therefore,the combined detection of HPV DNA+ Chemerin+ Leptin series can effectively improve the diagnostic efficiency,facilitate the early detection of cervical cancer,and early intervention.

参考文献/References:

[1] SCHIFFMAN M,WENTZENSEN N,WACHOLDER S,et al.Human papillomavirus testing in the prevention of cervical cancer[J].J Natl Cancer Inst,2011,103(5):368-383.
[2] 周琦,吴小华,刘继红,等.宫颈癌诊断与治疗指南(第四版)[J].中国实用妇科与产科杂志,2018,34(6):613-622. ZHOU Qi,WU Xiaohua,LIU Jihong,et al.Guidelines for the diagnosisand treatment of cervical cancer(4th Edition)[J].Chinese Journal of Practical Gynecology and Obstetrics,2018,34(6):613-622.
[3] CHELMOW D.Cervical cancer screening and prevention[J].Obstetrics & Gynecology,2016,127(1):e1-e20.
[4] 王冰,朱月蓉,何玉杰,等.血清结合珠蛋白在宫颈癌诊断中的应用研究[J].现代检验医学杂志,2017,32(1):106-108. WANG Bing,ZHU Yuerong,HE Yujie,et al.Application of haptoglobinin cervical cancer diagnosis[J].Journal of Modern Laboratory Medicine,2017,32(1):106-108.
[5] WARDAK S.Human papillomavirus(HPV)and cervical cancer[J].Medycyna Doswiadczalna I Mikrobiologia,2016,68(1):73-84.
[6] 林丽慧,唐梅,于春玲,等.HPV阳性宫颈癌和CIN患者血浆miR-150,SCCA及CA125的表达及临床意义[J].现代检验医学杂志,2018,33(2):62-65,69. LIN Lihui,TANG Mei,YU Chunling,et al.Expression and clinical significance of plasma miR-150,SCCA and CA125 in patients with HPV-positivecervical cancer and CIN[J].Journal of Modern Laboratory Medicine,2018,33(2):62-65,69.
[7] 吴孟水,宁翠利,刘宽芝.Chemerin的研究进展[J].医学综述,2016,22(11):2102-2106. WU Mengshui,NING Cuili,LIU Kuanzhi.The research progress of Chemerin[J].Medical Recapitulate,2016,22(11):2102-2106.
[8] 李杨,刘亚航,郭瑞芳.瘦素及脂联素在消化系统肿瘤中的研究进展[J].肿瘤研究与临床,2016,28(12):858-861. LI Yang,LIU Yahang,GUO Ruifang.Progress of leptin and adiponectin in digestive system neoplasms[J].Cancer Research and Clinic,2016,28(12):858-861.
[9] 中华人民共和国国家卫生和计划生育委员会.宫颈癌及癌前病变规范化诊疗指南(试行)[J].中国医学前沿杂志(电子版),2013,5(8):40-49. National Health and Family Planning Commission of the People's Republic of China.Standardized diagnosis and treatment guidelines for cervical cancer and precancerous lesions[J].Chinese Journal of the Frontiers of Medical Science(Electronic Version),2013,5(8):40-49.
[10] 郑建华.子宫颈癌FIGO分期的修订及治疗[C].//第七届全国子宫颈癌前病变、子宫颈癌热点研讨会.北京:北京大学妇产科系(中国妇产科临床杂志社),2010:108-109.ZHENG Jianhua.Revision and treatment of FIGO staging of cervical cancer[C]//Proceedings of 7th National Symposium on Cervical Prelesisons and CervicalCancer.Beijing:Beijing University Department of Obstetrics.Chinese Journal of Clinical Obstetrics and Gynecolog,2010:108-109.
[11] 刘婷婷,孔为民.宫颈癌治疗现状及进展[J].中国医师进修杂志,2016,39(1):82-84.LIU Tingting,KONG Weimin.Current status and progress of treatment of cervical cancer[J].Chinese Journal of Postgraduates of Medicine,2016,39(1):82-84.
[12] 曾琬琴,殷霞,狄文.宫颈癌的免疫治疗进展[J].国际妇产科学杂志,2017,44(6):681-685.ZENG Wanqin,YIN Xia,DI Wen.Advances in immunotherapy for cervical cancer[J].Journal International of Obstetrics and Gynecology,2017,44(6):681-685.
[13] 刘楚,姜育燊.HPV mRNA检测在宫颈癌诊断中的研究[J].标记免疫分析与临床,2016,23(10):1233-1236.LIU Chu,JIANG Yushen.HPV mRNA in diagnosis of cervical cancinoma[J].Labeled Immunoassays and Clinical Medicine,2016,23(10):1233-1236.
[14] 韩钦,韩红燕.宫颈癌筛查中HPV检测初筛的分流检测[J].实用妇产科杂志,2016,32(8):577-580.HAN Qin,HAN Hongyan.Cervical cancer screening screening test for HPV screening[J].Journal of Practical Obstetrics and Gynecology,2016,32(8):577-580.
[15] 刘雪峰,李堰松.血清Chemerin水平在宫颈上皮内瘤变及宫颈癌中的表达及临床意义[J].中国医师杂志,2016,18(1):81-83.LIU Xuefeng,LI Yansong.The expression and clinical significance of Chemerin in cervical intraepithelial neoplasia and cervical cancer[J].Journal of Chinese Physicians,2016,18(1):81-83.
[16] 张婧,朱明玥.血清瘦素与宫颈癌发生的相关性[J].实用医学杂志,2015,31(14):2357-2359.ZHANG Jing,ZHU Mingyue.The correlations between the leptin levels and the prevalence of cervical cancer[J].Journal of Practical Medicine,2015,31(14):2357-2359

相似文献/References:

[1]田英,王双勇,赵雅,等.宫颈癌组织细胞中Numb基因表达及相关性研究[J].现代检验医学杂志,2015,30(06):42.[doi:10.3969/j.issn.1671-7414.2015.06.012]
　TIAN Ying,WANG Shuang-yong,ZHAO Ya,et al.Study on Correlation and Expression of Numb Gene in Cervical Cancer[J].Journal of Modern Laboratory Medicine,2015,30(03):42.[doi:10.3969/j.issn.1671-7414.2015.06.012]
[2]顾益凤,朱自力,史跃燕,等.血浆硫氧还蛋白还原酶水平检测对宫颈癌早期诊断的价值研究[J].现代检验医学杂志,2019,34(02):40.[doi:10.3969/j.issn.1671-7414.2019.02.011]
　GU Yi-feng,ZHU Zi-li,SHI Yue-yan,et al.Study on the Value of Plasma Thioredoxin Reductase Levelin the Early Diagnosis of Cervical Cancer[J].Journal of Modern Laboratory Medicine,2019,34(03):40.[doi:10.3969/j.issn.1671-7414.2019.02.011]
[3]周　静,李　智,周　玉,等.宫颈癌组织中 Ep-CAM和 Ki67的表达及临床意义[J].现代检验医学杂志,2019,34(06):24.[doi:10.3969 ／ j.issn.1671-7414.2019.06.006]
　ZHOU Jing,LI Zhi,ZHOU Yu,et al.Expression and Clinicd Value of Ep-CAM and Ki67 in the Cervial Carcinoma Tissue[J].Journal of Modern Laboratory Medicine,2019,34(03):24.[doi:10.3969 ／ j.issn.1671-7414.2019.06.006]
[4]徐晓锋a,王　纯b,卢国丰a,等.宫颈癌患者 Kruppel 样因子 6，p21 蛋白表达水平与病理特征及化疗敏感性的相关性分析[J].现代检验医学杂志,2020,35(06):12.[doi:doi:10.3969/j.issn.1671-7414.2020.06.004]
　XU Xiao-feng a,WANG Chun b,LU Guo-feng a,et al.Correlation Analysis of KLF6 and p21 Protein Expression Levels andPathological Features and Chemotherapy Sensitivity in Patientswith Cervical Cancer[J].Journal of Modern Laboratory Medicine,2020,35(03):12.[doi:doi:10.3969/j.issn.1671-7414.2020.06.004]
[5]高红敏,杨红英,刘　鑫.血清中 microRNA-106b 对宫颈癌患者的早期诊断及预后预测价值[J].现代检验医学杂志,2020,35(06):85.[doi:doi:10.3969/j.issn.1671-7414.2020.06.020]
　GAO Hong-min,YANG Hong-ying,LIU Xin.Value Analysis of Serum microRNA-106b in Early Diagnosis ofCervical Cancer[J].Journal of Modern Laboratory Medicine,2020,35(03):85.[doi:doi:10.3969/j.issn.1671-7414.2020.06.020]
[6]赵白信,于慧娟,焦方杰,等.经阴道彩色多普勒超声联合血清 miR-130a，miR-425-5p 水平检测对宫颈癌的诊断效能分析[J].现代检验医学杂志,2021,36(03):43.[doi:10.3969/j.issn.1671-7414.2021.03.010]
　ZHAO Bai-xin,YU Hui-juan,JIAO Fang-jie,et al.Analysis of Diagnostic Efficacy of Transvaginal Color Doppler UltrasoundCombined with Serum miR-130a and miR-425-5p Levels in Cervical Cancer[J].Journal of Modern Laboratory Medicine,2021,36(03):43.[doi:10.3969/j.issn.1671-7414.2021.03.010]
[7]张治洋,李功娟.10株宫颈癌细胞系中MALAT1的表达及其对顺铂敏感性的影响[J].现代检验医学杂志,2021,36(05):110.[doi:10.3969/j.issn.1671-7414.2021.05.024]
　ZHANG Zhi-yang,LI Gong-juan.Expression of MALAT1 in 10 Cervical Cancer Cell Lines and Its Effect onCisplatin Sensitivity[J].Journal of Modern Laboratory Medicine,2021,36(03):110.[doi:10.3969/j.issn.1671-7414.2021.05.024]
[8]郝艳芳,刘亚荣,黄玲玲,等.miRNA-195靶向调控 CCND2和 MYB抑制宫颈癌细胞增殖、迁移的机制研究[J].现代检验医学杂志,2022,37(01):130.[doi:10.3969/j.issn.1671-7414.2022.01.026]
　HAO Yan-fang,LIU Ya-rong,HUANG Ling-ling,et al.Study on the Mechanism of miRNA-195 Targeting CCND2 and MYB to Inhibit the Proliferation and Migration of Cervical Cancer Cells[J].Journal of Modern Laboratory Medicine,2022,37(03):130.[doi:10.3969/j.issn.1671-7414.2022.01.026]
[9]方　芳,吴　玲,魏善闯,等.宫颈癌患者血清LCN2水平表达与HPV病毒载量及临床分期的相关研究[J].现代检验医学杂志,2022,37(02):80.[doi:10.3969/j.issn.1671-7414.2022.02.017]
　FANG Fang,WU Ling,WEI Shan-chuang,et al.Correlation of Expression of Serum LCN2 Level with HPV Load and Clinical Stage in Patients with Cervical Cancer[J].Journal of Modern Laboratory Medicine,2022,37(03):80.[doi:10.3969/j.issn.1671-7414.2022.02.017]
[10]谌媛媛,李 静.宫颈脱落细胞中PAX1 和SOX1 基因甲基化对宫颈癌实验诊断的临床研究[J].现代检验医学杂志,2022,37(06):46.[doi:10.3969/j.issn.1671-7414.2022.06.009]
　CHEN Yuan-yuan,LI Jing.Clinical Study of PAX1 and SOX1 Gene Methylation in Cervical Exfoliated Cells for Experimental Diagnosis of Cervical Cancer[J].Journal of Modern Laboratory Medicine,2022,37(03):46.[doi:10.3969/j.issn.1671-7414.2022.06.009]

备注/Memo

备注/Memo:
作者简介:陈 慎(1978-),男,汉,本科,主管技师,研究方向:临床检验,E-mail:Chenshenalien@126.com。 收稿日期:2018-10-15 修回日期:2018-11-07
更新日期/Last Update: 2019-06-20